193 related articles for article (PubMed ID: 25013997)
1. A reversible albumin-binding growth hormone derivative is well tolerated and possesses a potential once-weekly treatment profile.
Rasmussen MH; Olsen MW; Alifrangis L; Klim S; Suntum M
J Clin Endocrinol Metab; 2014 Oct; 99(10):E1819-29. PubMed ID: 25013997
[TBL] [Abstract][Full Text] [Related]
2. Reversible Albumin-Binding GH Possesses a Potential Once-Weekly Treatment Profile in Adult Growth Hormone Deficiency.
Rasmussen MH; Janukonyté J; Klose M; Marina D; Tanvig M; Nielsen LF; Höybye C; Andersen M; Feldt-Rasmussen U; Christiansen JS
J Clin Endocrinol Metab; 2016 Mar; 101(3):988-98. PubMed ID: 26727076
[TBL] [Abstract][Full Text] [Related]
3. Pegylated long-acting human growth hormone is well-tolerated in healthy subjects and possesses a potential once-weekly pharmacokinetic and pharmacodynamic treatment profile.
Rasmussen MH; Bysted BV; Anderson TW; Klitgaard T; Madsen J
J Clin Endocrinol Metab; 2010 Jul; 95(7):3411-7. PubMed ID: 20427496
[TBL] [Abstract][Full Text] [Related]
4. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
5. Somapacitan, a once-weekly reversible albumin-binding GH derivative, in children with GH deficiency: A randomized dose-escalation trial.
Battelino T; Rasmussen MH; De Schepper J; Zuckerman-Levin N; Gucev Z; Sävendahl L;
Clin Endocrinol (Oxf); 2017 Oct; 87(4):350-358. PubMed ID: 28656605
[TBL] [Abstract][Full Text] [Related]
6. Multiple doses of pegylated long-acting growth hormone are well tolerated in healthy male volunteers and possess a potential once-weekly treatment profile.
Rasmussen MH; Jensen L; Anderson TW; Klitgaard T; Madsen J
Clin Endocrinol (Oxf); 2010 Dec; 73(6):769-76. PubMed ID: 20718773
[TBL] [Abstract][Full Text] [Related]
7. Pegylated long-acting human growth hormone possesses a promising once-weekly treatment profile, and multiple dosing is well tolerated in adult patients with growth hormone deficiency.
Søndergaard E; Klose M; Hansen M; Hansen BS; Andersen M; Feldt-Rasmussen U; Laursen T; Rasmussen MH; Christiansen JS
J Clin Endocrinol Metab; 2011 Mar; 96(3):681-8. PubMed ID: 21177789
[TBL] [Abstract][Full Text] [Related]
8. Inhaled growth hormone (GH) compared with subcutaneous GH in children with GH deficiency: pharmacokinetics, pharmacodynamics, and safety.
Walvoord EC; de la Peña A; Park S; Silverman B; Cuttler L; Rose SR; Cutler G; Drop S; Chipman JJ
J Clin Endocrinol Metab; 2009 Jun; 94(6):2052-9. PubMed ID: 19336514
[TBL] [Abstract][Full Text] [Related]
9. Safety and convenience of once-weekly somapacitan in adult GH deficiency: a 26-week randomized, controlled trial.
Johannsson G; Feldt-Rasmussen U; Håkonsson IH; Biering H; Rodien P; Tahara S; Toogood A; Rasmussen MH;
Eur J Endocrinol; 2018 May; 178(5):491-499. PubMed ID: 29500310
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics, Pharmacodynamics, and Safety of a Long-Acting Human Growth Hormone (MOD-4023) in Healthy Japanese and Caucasian Adults.
Kramer WG; Jaron-Mendelson M; Koren R; Hershkovitz O; Hart G
Clin Pharmacol Drug Dev; 2018 Jun; 7(5):554-563. PubMed ID: 29136343
[TBL] [Abstract][Full Text] [Related]
11. A new sustained-release preparation of human growth hormone and its pharmacokinetic, pharmacodynamic and safety profile.
Jostel A; Mukherjee A; Alenfall J; Smethurst L; Shalet SM
Clin Endocrinol (Oxf); 2005 May; 62(5):623-7. PubMed ID: 15853836
[TBL] [Abstract][Full Text] [Related]
12. A first-in-man phase 1 trial for long-acting TransCon Growth Hormone.
Gilfoyle D; Mortensen E; Christoffersen ED; Leff JA; Beckert M
Growth Horm IGF Res; 2018 Apr; 39():34-39. PubMed ID: 29273485
[TBL] [Abstract][Full Text] [Related]
13. Pharmacokinetics and pharmacodynamics of once-weekly administration of JR-142, a long-acting albumin-fused human growth hormone: A rondemized, placebo-controlled phase 1 study.
Owada Y; Okazaki M; Ikeda T; Yamamoto R; Minami K; Takahashi K; Hirato T; Mita Y; Yamamoto T; Tanizawa K; Sonoda H; Sato Y
Growth Horm IGF Res; 2022 Dec; 67():101500. PubMed ID: 36113378
[TBL] [Abstract][Full Text] [Related]
14. Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers.
Bergman AJ; Stevens C; Zhou Y; Yi B; Laethem M; De Smet M; Snyder K; Hilliard D; Tanaka W; Zeng W; Tanen M; Wang AQ; Chen L; Winchell G; Davies MJ; Ramael S; Wagner JA; Herman GA
Clin Ther; 2006 Jan; 28(1):55-72. PubMed ID: 16490580
[TBL] [Abstract][Full Text] [Related]
15. The effect of four weeks of supraphysiological growth hormone administration on the insulin-like growth factor axis in women and men. GH-2000 Study Group.
Dall R; Longobardi S; Ehrnborg C; Keay N; Rosén T; Jørgensen JO; Cuneo RC; Boroujerdi MA; Cittadini A; Napoli R; Christiansen JS; Bengtsson BA; Sacca L; Baxter RC; Basset EE; Sönksen PH
J Clin Endocrinol Metab; 2000 Nov; 85(11):4193-200. PubMed ID: 11095453
[TBL] [Abstract][Full Text] [Related]
16. Once-Weekly Somapacitan vs Daily GH in Children With GH Deficiency: Results From a Randomized Phase 2 Trial.
Sävendahl L; Battelino T; Brod M; Højby Rasmussen M; Horikawa R; Juul RV; Saenger P;
J Clin Endocrinol Metab; 2020 Apr; 105(4):e1847-61. PubMed ID: 31917835
[TBL] [Abstract][Full Text] [Related]
17. Long-Acting C-Terminal Peptide-Modified hGH (MOD-4023): Results of a Safety and Dose-Finding Study in GHD Children.
Zelinska N; Iotova V; Skorodok J; Malievsky O; Peterkova V; Samsonova L; Rosenfeld RG; Zadik Z; Jaron-Mendelson M; Koren R; Amitzi L; Raduk D; Hershkovitz O; Hart G
J Clin Endocrinol Metab; 2017 May; 102(5):1578-1587. PubMed ID: 28323965
[TBL] [Abstract][Full Text] [Related]
18. A long-acting pegylated recombinant human growth hormone (Jintrolong
Guan Y; He F; Wu J; Zhao L; Wang X; Huang L; Zeng G; Ren B; Chen J; Liao X; Ma Z; Chen X; Zhong G; Huang M; Zhao X
J Clin Pharm Ther; 2018 Oct; 43(5):640-646. PubMed ID: 29959799
[TBL] [Abstract][Full Text] [Related]
19. MOD-4023, a long-acting carboxy-terminal peptide-modified human growth hormone: results of a Phase 2 study in growth hormone-deficient adults.
Strasburger CJ; Vanuga P; Payer J; Pfeifer M; Popovic V; Bajnok L; Góth M; Olšovská V; Trejbalová L; Vadasz J; Fima E; Koren R; Amitzi L; Bidlingmaier M; Hershkovitz O; Hart G; Biller BMK
Eur J Endocrinol; 2017 Mar; 176(3):283-294. PubMed ID: 27932411
[TBL] [Abstract][Full Text] [Related]
20. Intranasal Human Growth Hormone (hGH) Induces IGF-1 Levels Comparable With Subcutaneous Injection With Lower Systemic Exposure to hGH in Healthy Volunteers.
Lewis AL; Jordan F; Patel T; Jeffery K; King G; Savage M; Shalet S; Illum L
J Clin Endocrinol Metab; 2015 Nov; 100(11):4364-71. PubMed ID: 26425883
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
